A randomised double-blind trial to determine the bleeding profile of the prolonged-release contraceptive dienogest 2 mg/ethinylestradiol 0.02 mg versus an immediate-release formulation of drospirenone 3 mg/ethinylestradiol 0.02 mg
The prolonged-release DNG 2 mg/EE 0.02 mg offers a significant decrease in unscheduled bleeding/spotting compared with an immediate-release COC, DRSP/EE, combined with high contraceptive efficacy and a very low adverse event profile.
Authors
- Pedro‐Antonio Regidor (ORCID: https://orcid.org/0000-0002-9551-2847)
- Anne E. Burke (ORCID: https://orcid.org/0009-0009-4849-1068)
- Kristina Biskupska-Bodova
- Tamás Nyirády
- Alicyoy Angulo
- Joanna Sójka-Kupny
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Mediciti Institute of Medical Sciences (IN)
- Hirslanden Private Hospital Group (CH)
- IS practice (BE)
- Chemopharma (Austria) (AT)
- Martin University Hospital (SK)
Publication Details
- Journal
- The European Journal of Contraception & Reproductive Health Care
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1080/13625187.2024.2398433
- Citations
- 10
- Primary Topic
- Reproductive Health and Contraception
- Type
- article
- Field-Weighted Citation Impact
- 5.43